Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

Exclusion Criteria

• •Known intolerance, contraindication to, or history of non-compliance with Avonex® 30 µg
• •History of treatment with Daclizumab High Yield Process (Dac HYP)
• •History of malignancy
• •History of severe allergic or anaphylactic reactions
• •Known hypersensitivity to study drugs or their excipients
• •History of abnormal laboratory results indicative of any significant disease
• •History of human immunodeficiency virus (HIV) or other immunodeficient conditions
• •History of drug or alcohol abuse (as defined by the Investigator) within the 2 years prior to randomization
• •History of seizure disorder or unexplained blackouts OR history of a seizure within 6 months prior to Baseline
• •History of suicidal ideation or an episode of clinically severe depression (as determined by the Investigator) within 3 months prior to Day 1
• •An MS relapse that has occurred within the 50 days prior to randomization AND/OR the subject has not stabilized from a previous relapse prior to randomization
• •Known history of, or positive screening test result for hepatitis C virus or hepatitis B virus
• •Varicella or herpes zoster virus infection or any severe viral infection within 6 weeks before screening
• •Exposure to varicella zoster virus within 21 days before screening